Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13)

Bossuyt, Xavier; Vulsteke, Jean‐Baptiste; Elslande, Jan Van; Boon, Lise; Wuyts, Greet; Willebrords, Silke; Frans, Glynis; Geukens, Nick; Carpentier, Sébastien; Tejpar, Sabine; Wildiers, Hans; Blockmans, Daniel Engelbert; Langhe, Ellen De; Vermeersch, Pieter; Derua, Rita

doi:10.1016/j.autrev.2023.103288

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential role of autoimmunity and uncontrolled inflammation in COVID-19 severity highlights the importance of considering these factors in therapeutic strategies. More research is needed to better understand the complex interaction between SAD and COVID-19-this is also reflected by the recent discovery of SAD-and cancer-specific antinuclear antibodies in COVID-19 patients [94]. Moreover, Böröcz et al recently reported compounddependent expression levels of natural autoantibodies after COVID-19 vaccination [95].…”

Section: Immune Dysregulation and Severity Of Covid-19 Infectionmentioning

confidence: 99%

Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

Solimando

Bittrich

Shahini

et al. 2023

IJMS

View full text Add to dashboard Cite

At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders—including patients suffering from cancer—were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.

show abstract

Section: Immune Dysregulation and Severity Of Covid-19 Infectionmentioning

confidence: 99%

Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

Solimando

Bittrich

Shahini

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…IP-MS represents a powerful tool for the discovery novel autoantibodies and as an approach to closing the seronegative gap in AIM [24,[36][37][38]. However, the significance of such findings is highly dependent on the selection of an appropriate reference or comparator group [39] and newly identified autoantibodies would be most clinically useful if they can be ported to more conventional in vitro diagnostic platforms such as ELISA [40], LIA [28], ALBIA or PMAT [26,41,42].…”

Section: Key Pointsmentioning

confidence: 99%

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Choi,

Satoh,

Fritzler

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review This manuscript reviews recently published advances in the identification of autoimmune inflammatory myopathies (AIM)-specific and AIM-related autoantibodies considered of value in the workup of patients suspected of having AIM. Newer autoantibodies, developments, and advances in the methodology of testing, the gaps and pitfalls in using these assays as diagnostic biomarkers, and the importance of considering overlap diseases and unique clinical AIM phenotypes are discussed. Recent findings Summary The spectrum of autoantibodies and related biomarkers in AIM continues to expand. Many of these have clear clinical implications in regard to subsets and overlap conditions of AIM, associated malignancy and pathological findings.

show abstract

Nouveaux auto-anticorps dans la myosite auto-immune et la sclérodermie systémique

Bossuyt

2024

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

Antinuclear antibodies in individuals with COVID-19 reflect underlying disease: Identification of new autoantibodies in systemic sclerosis (CDK9) and malignancy (RNF20, RCC1, TRIP13)

Cited by 3 publications

References 32 publications

Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer

Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies

Nouveaux auto-anticorps dans la myosite auto-immune et la sclérodermie systémique

Contact Info

Product

Resources

About